Qiu‐Xu Teng

2.1k total citations · 3 hit papers
50 papers, 1.6k citations indexed

About

Qiu‐Xu Teng is a scholar working on Oncology, Molecular Biology and Infectious Diseases. According to data from OpenAlex, Qiu‐Xu Teng has authored 50 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Oncology, 29 papers in Molecular Biology and 20 papers in Infectious Diseases. Recurrent topics in Qiu‐Xu Teng's work include Drug Transport and Resistance Mechanisms (43 papers), Cancer therapeutics and mechanisms (24 papers) and HIV/AIDS drug development and treatment (20 papers). Qiu‐Xu Teng is often cited by papers focused on Drug Transport and Resistance Mechanisms (43 papers), Cancer therapeutics and mechanisms (24 papers) and HIV/AIDS drug development and treatment (20 papers). Qiu‐Xu Teng collaborates with scholars based in United States, China and Israel. Qiu‐Xu Teng's co-authors include Zhe‐Sheng Chen, Zi‐Ning Lei, Jing‐Quan Wang, Yuqi Yang, Zhuo‐Xun Wu, Chao‐Yun Cai, Leli Zeng, Yihang Pan, Qingbin Cui and John N.D. Wurpel and has published in prestigious journals such as SHILAP Revista de lepidopterología, Cancer Research and International Journal of Molecular Sciences.

In The Last Decade

Qiu‐Xu Teng

50 papers receiving 1.6k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Understanding and targeting resistance mechanisms in cancer

2023 177 citations Zi‐Ning Lei, Tian Qin et al. SHILAP Revista de lepidopterología profile →
Multidrug resistance proteins (MRPs): Structure, function and the overcoming of cancer multidrug resistance

2021 171 citations Jing‐Quan Wang, Yuqi Yang et al. profile →
Signaling pathways and therapeutic interventions in gastric cancer

2022 167 citations Zi‐Ning Lei, Qiu‐Xu Teng et al. Signal Transduction and Targeted Therapy profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Qiu‐Xu Teng	964	932	261	206	164	50	1.6k
Rishil J. Kathawala	1.2k 1.2×	904 1.0×	183 0.7×	236 1.1×	171 1.0×	31	1.7k
Jean‐Pierre Gillet	876 0.9×	1.0k 1.1×	231 0.9×	136 0.7×	110 0.7×	29	1.7k
Chao‐Yun Cai	849 0.9×	862 0.9×	179 0.7×	210 1.0×	150 0.9×	40	1.6k
Zi‐Ning Lei	1.2k 1.3×	1.2k 1.3×	306 1.2×	322 1.6×	200 1.2×	72	2.2k
Elizabeth Hopper-Borge	954 1.0×	638 0.7×	132 0.5×	289 1.4×	243 1.5×	20	1.5k
György Várady	989 1.0×	804 0.9×	98 0.4×	149 0.7×	203 1.2×	73	1.7k
Yong‐ju Liang	1.4k 1.4×	1.1k 1.2×	171 0.7×	220 1.1×	133 0.8×	43	2.2k
Chun-ling Dai	992 1.0×	695 0.7×	104 0.4×	184 0.9×	145 0.9×	19	1.4k
Kieran L. O’Loughlin	928 1.0×	764 0.8×	120 0.5×	219 1.1×	230 1.4×	33	1.7k
Yi‐Jun Wang	1.6k 1.7×	982 1.1×	215 0.8×	209 1.0×	128 0.8×	75	2.5k

Countries citing papers authored by Qiu‐Xu Teng

Since Specialization

Citations

This map shows the geographic impact of Qiu‐Xu Teng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Qiu‐Xu Teng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Qiu‐Xu Teng more than expected).

Fields of papers citing papers by Qiu‐Xu Teng

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Qiu‐Xu Teng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Qiu‐Xu Teng. The network helps show where Qiu‐Xu Teng may publish in the future.

Co-authorship network of co-authors of Qiu‐Xu Teng

This figure shows the co-authorship network connecting the top 25 collaborators of Qiu‐Xu Teng. A scholar is included among the top collaborators of Qiu‐Xu Teng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Qiu‐Xu Teng. Qiu‐Xu Teng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zhang, Meng, Qiu‐Xu Teng, Zi‐Ning Lei, et al.. (2024). Mobocertinib antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells: In vitro and in vivo studies. Cancer Letters. 607. 217309–217309. 6 indexed citations

Cai, Chao‐Yun, Zhuo‐Xun Wu, Qiu‐Xu Teng, et al.. (2023). Design, synthesis, and biological evaluation of phenylurea indole derivatives as ABCG2 inhibitors. Bioorganic Chemistry. 135. 106481–106481. 7 indexed citations

Lei, Zi‐Ning, Tian Qin, Qiu‐Xu Teng, et al.. (2023). Understanding and targeting resistance mechanisms in cancer. SHILAP Revista de lepidopterología. 4(3). e265–e265. 177 indexed citations breakdown →

Cai, Chao‐Yun, et al.. (2023). Design, Synthesis and Biological Evaluation of Quinazolinamine Derivatives as Breast Cancer Resistance Protein and P-Glycoprotein Inhibitors with Improved Metabolic Stability. Biomolecules. 13(2). 253–253. 6 indexed citations

Wang, Saiqi, Qiu‐Xu Teng, Shuai Wang, et al.. (2022). Preclinical studies of the triazolo[1,5-a]pyrimidine derivative WS-716 as a highly potent, specific and orally active P-glycoprotein (P-gp) inhibitor. Acta Pharmaceutica Sinica B. 12(8). 3263–3280. 24 indexed citations

Lei, Zi‐Ning, Qiu‐Xu Teng, Tian Qin, et al.. (2022). Signaling pathways and therapeutic interventions in gastric cancer. Signal Transduction and Targeted Therapy. 7(1). 358–358. 167 indexed citations breakdown →

Wang, Jing‐Quan, Zhuo‐Xun Wu, Yuqi Yang, et al.. (2021). ATP‐binding cassette (ABC) transporters in cancer: A review of recent updates. Journal of Evidence-Based Medicine. 14(3). 232–256. 105 indexed citations

Lei, Zi‐Ning, Qiu‐Xu Teng, Zhuo‐Xun Wu, et al.. (2021). Overcoming multidrug resistance by knockout of ABCB1 gene using CRISPR/Cas9 system in SW620/Ad300 colorectal cancer cells. SHILAP Revista de lepidopterología. 2(4). 765–777. 36 indexed citations

Narayanan, Silpa, Yingfang Fan, Qiu‐Xu Teng, et al.. (2021). VKNG-1 Antagonizes ABCG2-Mediated Multidrug Resistance via p-AKT and Bcl-2 Pathway in Colon Cancer: In Vitro and In Vivo Study. Cancers. 13(18). 4675–4675. 8 indexed citations

10.

Wang, Shuai, Saiqi Wang, Qiu‐Xu Teng, et al.. (2021). Discovery of the Triazolo[1,5-a]Pyrimidine-Based Derivative WS-898 as a Highly Efficacious and Orally Bioavailable ABCB1 Inhibitor Capable of Overcoming Multidrug Resistance. Journal of Medicinal Chemistry. 64(21). 16187–16204. 29 indexed citations

11.

Wu, Zhuo‐Xun, Qiu‐Xu Teng, Yuqi Yang, et al.. (2021). MET inhibitor tepotinib antagonizes multidrug resistance mediated by ABCG2 transporter: In vitro and in vivo study. Acta Pharmaceutica Sinica B. 12(5). 2609–2618. 16 indexed citations

12.

Wang, Jing‐Quan, Bo Wang, Qiu‐Xu Teng, et al.. (2021). CMP25, a synthetic new agent, targets multidrug resistance-associated protein 7 (MRP7/ABCC10). Biochemical Pharmacology. 190. 114652–114652. 5 indexed citations

13.

Wu, Zhuo‐Xun, Yuqi Yang, Guangsuo Wang, et al.. (2020). Dual TTK/CLK2 inhibitor, CC‐671, selectively antagonizes ABCG2‐mediated multidrug resistance in lung cancer cells. Cancer Science. 111(8). 2872–2882. 28 indexed citations

14.

Wu, Zhuo‐Xun, Yuqi Yang, Qiu‐Xu Teng, et al.. (2020). Tivantinib, A c-Met Inhibitor in Clinical Trials, Is Susceptible to ABCG2-Mediated Drug Resistance. Cancers. 12(1). 186–186. 38 indexed citations

15.

Wang, Jing‐Quan, Qiu‐Xu Teng, Zi‐Ning Lei, et al.. (2020). Venetoclax, a BCL-2 Inhibitor, Enhances the Efficacy of Chemotherapeutic Agents in Wild-Type ABCG2-Overexpression-Mediated MDR Cancer Cells. Cancers. 12(2). 466–466. 48 indexed citations

16.

Wang, Jingqiu, Dong‐Hua Yang, Yuqi Yang, et al.. (2020). Overexpression of ABCB1 Transporter Confers Resistance to mTOR Inhibitor WYE-354 in Cancer Cells. International Journal of Molecular Sciences. 21(4). 1387–1387. 33 indexed citations

17.

Wang, Shuai, Saiqi Wang, Qiu‐Xu Teng, et al.. (2020). Structure-Based Design, Synthesis, and Biological Evaluation of New Triazolo[1,5- a ]Pyrimidine Derivatives as Highly Potent and Orally Active ABCB1 Modulators. Journal of Medicinal Chemistry. 63(24). 15979–15996. 41 indexed citations

18.

Yang, Yuqi, Ning Ji, Chao‐Yun Cai, et al.. (2020). Modulating the function of ABCB1: in vitro and in vivo characterization of sitravatinib, a tyrosine kinase inhibitor. Cancer Communications. 40(7). 285–300. 31 indexed citations

19.

Wu, Zhuo‐Xun, Qiu‐Xu Teng, Chao‐Yun Cai, et al.. (2019). Tepotinib reverses ABCB1-mediated multidrug resistance in cancer cells. Biochemical Pharmacology. 166. 120–127. 57 indexed citations

20.

Gupta, Pranav, Zi‐Ning Lei, Dan Liao, et al.. (2018). Immuno-oncology agent IPI-549 is a modulator of P-glycoprotein (P-gp, MDR1, ABCB1)-mediated multidrug resistance (MDR) in cancer: In vitro and in vivo. Cancer Letters. 442. 91–103. 49 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact